ArticleIranian journal of pharmaceutical research : IJPR2018
Antitumor Effects of Umbelliprenin in a Mouse Model of Colorectal Cancer.
Article in Iranian journal of pharmaceutical research : IJPR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis.Scientific reports · 2024Pooled it
- Umbelliprenin co-formulated with selenium nanoparticles downregulates MMP-2, MMP-9 and ICAM-1 expression in triple-negative breast cancer cells MDA-MB-231.BMC complementary medicine and therapies · 2026Article
- Exploring Natural Coumarins: Breakthroughs in Anticancer Therapeutics.Anti-cancer agents in medicinal chemistry · 2026Review
- Novel Products as Promising Therapeutic Agents for Angiogenesis Inhibition.Current drug delivery · 2025Review
- Untargeted Metabolomics Analysis of Vaginal Secretion Reveals Potential Pathogenesis of Atrophic Vaginitis.Current pharmaceutical design · 2025Article
- Study of the anti-cancer activity of a mesoporous silica nanoparticle surface coated with polydopamine loaded with umbelliprenin.Scientific reports · 2024Article
- Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness.Biomedicines · 2024Review
- Impact of umbelliprenin-containing niosome nanoparticles onInternational journal of ophthalmology · 2024Article
- Umbelliprenin induces autophagy and apoptosis while inhibits cancer cell stemness in pancreatic cancer cells.Cancer medicine · 2023Article
- Natural Products: A Promising Therapeutics for Targeting Tumor Angiogenesis.Frontiers in oncology · 2021Review
- Umbelliprenin Increases the M1/M2 Ratio of Macrophage Polarization and Improves the M1 Macrophage Activity in THP-1 Cells Cocultured with AGS Cells.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin.Biomedicines · 2020Review
- Metabolic Profile, Bioactivities, and Variations in the Chemical Constituents of Essential Oils of theFrontiers in pharmacology · 2020Review
- Antiangiogenic Effects of Coumarins against Cancer: From Chemistry to Medicine.Molecules (Basel, Switzerland) · 2019Review
- Umbelliprenin, a bioactive constituent from the genusAvicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Umbelliprenin is a sesquiterpene coumarin with vitro anti-carcinogenic activities. The aim of this study was to investigate the antitumor effects of umbelliprenin in animal models of colorectal cancer. The cytotoxic effects of umbelliprenin were explored on CT26 and L929by MTT assay. In this study, colorectal tumors developed in mice by intradermal injection of CT26 cell line. Tumor size, serum levels of IFN-γ and IL-4 by ELISA, and Ki-67, MMP2, MMP9, VEGF and E-cadherin markers by IHC method were evaluated. The results showed that umbelliprenin inhibited the cancer cells in a concentration-dependent manner. IC50 Evaluation showed that L929 cells were more resistant to Umbelliprenin than CT26 cells. Umbelliprenin treatment in both tumor-bearing mice and control normal mice showed significantly increased IFN-γ and decreased IL-4(
Indexed as
Identifiers
30127820PMC6094438W2891669729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.